- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02120404
Pilot Phase II Study: Hemodynamic Tolerance and Anti-inflammatory Effects of Esmolol During the Treatment of Septic Shock (THANE)
The purpose of this study is :
- to evaluate the hemodynamic tolerance of esmolol titrated to obtain a lowering of heart rate of 10% or 20%.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
During septic shock, the consequences of treatment by a β1-blocker on inflammation and cardiovascular variability are unknown. The use of esmolol should have positive effects on inflammation and hemodynamic tolerance. These effects are probably dose-dependent.
The study will enroll adult patients hospitalized in ICU, for severe septic shock requiring treatment by a vasopressor.
A total of 45 patients will be included. Among these 45 patients, 15 patients will be randomized in the control group. 30 patients will be randomized to Esmolol with the objective to decrease heart rate by 10% (Group G10, n=15) or 20% (Group G20, n=15). Esmolol will be administered for 24 hours.
This multicenter study will be performed in 3 investigation sites.
The following parameters will be evaluated at different moments during the 28 days follow up of each patient, mainly:
- Origin of sepsis, SOFA score.
- Hemodynamic parameters will be continuously recorded for the 24 hours of experimental period.
- Cardiovascular variability (arterial pressure and heart rate) will be recorded for 24 hours.
- 3 echocardiograms at H0, H12 and H24 will be performed.
Biological parameters will be sampled at H0, H6, H12 and H24: They include standard biological parameters (Urea, Creatinin, Bilirubin,……) and specific parameters (catecholamines, vasopressin, insulin, cortisol, proinflammatory cytokines and anti-inflammatory cytokines. Dosages will be performed only at H0, H12 and H24 in order to study:
- The expression of adrenergic receptors and their genetic polymorphisms on circulating immune cells.
- The Th1/Th2 balance in immune cells.
Each patient will be followed-up for 28 days.
The variation of MAP and of cardiac output induced by esmolol should not exceed 15% of baseline values. If the variation is more important esmolol administration will be stopped and the hemodynamical tolerance will be defined as poor.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Haute Des Seine
-
Garches, Haute Des Seine, France, 92380
- ICU, Hôpital Raymond Poincaré
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient aged ≥ 18 years;
- Patient with septic shock;
- Patient with arterial catheter, central venous catheter with PVC and PiCCO;
- Consent signed by patient. In the absence of a consent signed by patient himself, a consent by a family member will be sought. As soon as possible, the patient will be informed and asked to sign a consent for continuing of study;
- Hemodynamic stability of patient during 1 hour without change in norepinephrine dosage;
- Treatment with noradrenaline for less than 48 hours.
Exclusion Criteria:
- Need of noradrenaline > 3 mg/h;
- Treatment with dobutamine;
- Personal history of severe asthma;
- Personal history of severe chronic obstructive pulmonary disease;
- Personal history of pulmonary hypertension;
- Personal history of second degree or third degree atrioventricular block without pacemaker;
- Personal history of sinoatrial block without pacemaker;
- Chronic heart failure with ejection fraction < 40%;
- Severe atrioventricular nodal bradycardia (heart rate < 70 bpm);
- Mean arterial pressure < 65 mm Hg;
- Hypersensitivity to esmolol;
- Prinzmetal angina;
- Pheochromocytoma without treatment;
- Pregnancy woman;
- Breastfeeding woman;
- Peripheral arterial disease;
- Patient with pacemaker;
- Chronic treatment with a beta blocker;
- Concomitant treatment with bepridil, diltiazem, verapamil, amiodarone, propafenone, Class Ia antiarrythmics (hydroquinidine, disopyramide) or baclofen;
- Patient < 18 years;
- Patient under the care of a guardian;
- Therapeutic futility;
- Lack of medical insurance.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Control group (GC)
Control group: no esmolol administration
|
|
Experimental: Group 10 (G10)
Esmolol titrated in order to reduce heart rate by 10% as compared to baseline heart rate
|
Esmolol will be administered during 24 hours, beginning with a titration period to determine the minimal dose allowing to achieve the randomized heart rate reduction of 10% or 20%, as defined by randomization. Titration will be performed in sequences of increasing doses, beginning with 5 μg/kg/min as initial dose, and increasing by 5 μg/kg/min each 30 minutes until the target heart rate reduction is obtained. The maximum dose is 200 μg/kg/min. The titrated dose will be maintained for a total duration of 24 hours.
Other Names:
|
Experimental: Group 20 (G20)
Esmolol titrated in order to reduce heart rate by 20% as compared to baseline heart rate
|
Esmolol will be administered during 24 hours, beginning with a titration period to determine the minimal dose allowing to achieve the randomized heart rate reduction of 10% or 20%, as defined by randomization. Titration will be performed in sequences of increasing doses, beginning with 5 μg/kg/min as initial dose, and increasing by 5 μg/kg/min each 30 minutes until the target heart rate reduction is obtained. The maximum dose is 200 μg/kg/min. The titrated dose will be maintained for a total duration of 24 hours.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of hemodynamic parameters between 3 groups
Time Frame: 24 hours
|
3 groups: GC, G10 and G20. The hemodynamic tolerance will be considered as satisfactory if the variation of MAP and cardiac output induced by esmolol does not exceed 15% of baseline (H0). |
24 hours
|
Immunomodulatory effect
Time Frame: 24 hours
|
Immunomodulatory effect of esmolol will be evaluated notably by the ratio of IL6 / IL10. The decrease of this ratio in comparison with the value at baseline (H0) will be considered as an indicator of esmolol efficacy as immunomodulator. |
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Comparison of number and severity of organ failures, between the 3 groups
Time Frame: 28 days
|
3 groups will be evaluated by SOFA score.
|
28 days
|
Comparison of autonomic nervous system activity between the 3 groups
Time Frame: 24 hours
|
Power spectrum analysis of heart rate variability.
|
24 hours
|
Comparison of mortality in the 3 groups
Time Frame: 28 days
|
28 days
|
|
Comparison in the 3 groups of the correlations between the biomarkers and the hemodynamic data
Time Frame: 24 hours
|
The biomarkers in plasma levels: cortisol, catecholamine, proinflammatory cytokines and anti-inflammatory cytokines.
|
24 hours
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Djillali ANNANE, MD, PhD, ICU, Hôpital Raymond Poincaré, 92380 Garches, France
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Infections
- Systemic Inflammatory Response Syndrome
- Inflammation
- Sepsis
- Shock, Septic
- Shock
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Adrenergic beta-1 Receptor Antagonists
- Esmolol
Other Study ID Numbers
- P120912
- 2013-005174-22 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Septic Shock
-
German Center for Neurodegenerative Diseases (DZNE)University Hospital, BonnUnknownSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockGermany
-
University Medicine GreifswaldUnknownSepsis Septic ShockGermany
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
McMaster UniversityCanadian Institutes of Health Research (CIHR); The Physicians' Services Incorporated...Recruiting
-
Assistance Publique - Hôpitaux de ParisCompletedSeptic Shock HyperdynamicFrance
-
Centre Hospitalier Universitaire DijonCompleted
-
Mansoura UniversityUnknown
-
National Taiwan University HospitalBaxter Healthcare CorporationRecruiting
-
Charite University, Berlin, GermanyCompleted
-
University of ZurichCompletedPatients in Septic ShockSwitzerland
Clinical Trials on Esmolol administration
-
Consorcio Centro de Investigación Biomédica en...Instituto de Salud Carlos IIIRecruitingDiabetes Mellitus | Cirrhosis | Oncologic DisordersSpain
-
Hospital de Clinicas de Porto AlegreUnknown
-
Aretaieion University HospitalRecruitingPain, Postoperative | Analgesia | Pain, Acute | Nociceptive Pain | Inguinal Hernia Repair | Pain, Chronic Post-Surgical | EsmololGreece
-
AOP Orphan Pharmaceuticals AGCompletedHealthy Volunteers | Pharmacokinetics/Dynamics StudyCzech Republic
-
David N. Proctor, PhDCompleted
-
Hadassah Medical OrganizationUnknownDecrease in Heart Rate Below Baseline ValueIsrael
-
Hospital de BaseUnknownHemodynamic Instability | Beta BlockerBrazil
-
Novalead Pharma Private LimitedCompletedDiabetic Foot UlcerIndia
-
Centre Hospitalier Universitaire de NīmesWithdrawn
-
AOP Orphan Pharmaceuticals AGCompleted